Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $207.00

Becton, Dickinson and Company (NYSE:BDX) had its target price boosted by Bank of America from $190.00 to $207.00 in a research report report published on Monday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

BDX has been the subject of several other reports. Stifel Nicolaus cut their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Piper Sandler lowered their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Finally, Jefferies Financial Group raised their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Trading Down 1.3%

Becton, Dickinson and Company stock opened at $202.74 on Monday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm has a market capitalization of $57.76 billion, a PE ratio of 34.78, a PEG ratio of 2.27 and a beta of 0.23. The business’s 50-day simple moving average is $192.11 and its 200-day simple moving average is $187.77.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.32 billion for the quarter. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a $1.05 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 629 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,052 shares of company stock worth $201,235 in the last 90 days. Company insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently bought and sold shares of BDX. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in shares of Becton, Dickinson and Company by 7.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 5,323 shares of the medical instruments supplier’s stock valued at $1,219,000 after purchasing an additional 350 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Becton, Dickinson and Company by 8.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,735 shares of the medical instruments supplier’s stock valued at $5,895,000 after purchasing an additional 2,034 shares during the period. NewEdge Advisors LLC increased its stake in Becton, Dickinson and Company by 5.5% during the 1st quarter. NewEdge Advisors LLC now owns 17,443 shares of the medical instruments supplier’s stock worth $3,995,000 after purchasing an additional 904 shares in the last quarter. Finally, UniSuper Management Pty Ltd raised its holdings in Becton, Dickinson and Company by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 21,557 shares of the medical instruments supplier’s stock worth $4,938,000 after buying an additional 346 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.